Abstract. MicroRNA (miR)-150 has been demonstrated to protect the heart from ischemic injury. However, the protective effect of miR-150 in hypoxia-injured cardiomyocytes remains unclear. The present study aimed to investigate the target gene of miR-150 and the underlying molecular mechanisms of miR-150 in hypoxia-induced cardiomyocyte apoptosis. Using the hypoxia model of human cardiomyocytes (HCMs) in vitro, it was demonstrated that miR-150 was markedly inhibited in HCMs after hypoxia treatment. Overexpressing miR-150 significantly decreased hypoxia-induced HCM death and apoptosis. In addition, GRP94 was revealed to be a direct target of miR-150. Additionally, GRP94 was demonstrated to be involved in hypoxia-induced HCM apoptosis, and the protein expression levels of GRP94 were increased in HCMs in the presence of hypoxia. These findings demonstrated that miR-150 is involved in hypoxia-mediated gene regulation and apoptosis in HCMs. Furthermore, GRP94 knockout increased the cell viability of hypoxia-impaired HCMs with miR-150 mimic or miR-150 inhibitor transfection. In conclusion, miR-150 may serve a protective role in cardiomyocyte hypoxia injury, and the underlying mechanism was mediated, at least partially, by inhibiting GRP94 expression. These findings may provide a novel insight for the therapy of hypoxia-induced myocardial I/R injury.
Introduction
The cardiovascular system provides blood flow to tissues, which delivers oxygen and nutrients to maintain normal metabolism for cells (1) . Restriction of cardiac blood flow results in myocardial ischemia, which can trigger ischemia/reperfusion (I/R) injury, such as myocardial infarction and hemorrhage shock (2) . The decrease in myocardial oxygen tension and rise in carbon dioxide tension contribute to the initiation of cell death by increasing generation of reactive oxygen species (ROS), disruption of calcium homeostasis, depletion of glycogen stores, mitochondrial injury and oxidative damage to DNA (3) (4) (5) . The apoptosis of cardiomyocytes serves a vital role in the development of various biological and pathological processes, including ischemic injuries (6) . Therefore, maintenance of normal myocardial cell function is of great significance for the treatment of myocardial ischemic injuries.
MicroRNAs (miRs) are a class of small non-coding RNA (18-25 nucleotides) molecules that regulate the translation of messenger RNAs (mRNAs) by binding to the 3'-untranslated regions (3'-UTR) of target mRNAs (7) . Multiple studies have demonstrated that the pathogenic change in various tissues of humans has been associated with abnormal miR expression (8, 9) . Notably, miRs have provided novel insights into hypoxia-induced myocardial cell dysfunction (10) . It has been reported that miR-7a/b attenuates post-myocardial infarction remodeling and protects H9c2 cardiomyoblast against hypoxia-induced apoptosis, involving specificity protein 1 and poly (ADP-ribose) polymerase-1 (11) . miR-221 is involved in survival of hypoxia preconditioned ventricular myocytes through the DNA damage-inducible transcript 4 protein/mechanistic target of rapamycin complex 1 and tumor protein p53-inducible nuclear protein 1/p62 signaling pathways (12) . miR-21 and miR-146a synergistically decrease apoptosis under ischemia/hypoxic conditions in cardiomyocytes (13) . However, the role of miRNAs in regulating hypoxia-induced myocardial cell injury has not been completely clarified and requires further investigation. Previous studies indicated that miR-150 protects the heart from injury by inhibiting monocyte accumulation and cell death in a mouse model of acute myocardial infarction (14, 15) . However, the specific role of miR-150 in hypoxia-induced myocardial cell dysfunction remains unknown.
Glucose-regulated protein-94 (GRP94) is a most abundant glycoprotein in the endoplasmic reticulum (ER), and is involved in the maintenance of cell survival by protecting against stresses due to Ca 2+ depletion from the ER (16, 17) . A previous study demonstrated that GRP94 is expressed in the sarcoplasmic reticulum (SR) of adult rabbit cardiomyocytes (18) . GRP94 is reported to protect cardiomyocytes from both Overexpressing microRNA-150 attenuates hypoxia-induced human cardiomyocyte cell apoptosis by targeting glucose-regulated protein-94 ischemia and calcium overload (19) . However, the underlying molecular mechanisms of GRP94 in hypoxia-induced myocardial cell dysfunction have not been previously addressed. The present study demonstrated that miR-150 could regulate GRP94 expression by targeting to the 3'-UTR of GRP94, suggesting that a post-translational mechanism may exist for regulating GRP94 expression by miR-150 in hypoxia-treated cardiomyocytes, which might provide a potential therapeutic treatment for I/R injury. 
Materials and methods

Cell
Measurement of lactate dehydrogenase (LDH) activity.
The LDH activity in the culture medium was detected using an LDH assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing China) for the measurement of cell injury, according to the manufacturer's protocol.
Caspase-3 activity and cell apoptosis assay. HCMs lysates were prepared and incubated with an anti-caspase 3 antibody (cat. no. sc7272; 1:200; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 37˚C for 1 h. Immunocomplexes were incubated with peptide substrate in assay buffer for 2 h at 37˚C. Release of p-nitroaniline was measured at 405 nm using an ELISA reader (MD SpectraMax M5) according to the manufacturer's protocol.
miR target prediction. The potential binding site between miR-124 and MCP-1 were obtained using online predict software (miRanda-mirSVR; http://www.microrna.org), miRDB (http://www.mirdb.org/miRDB/) and TargetScan (http://www.targetscan.org/).
Retrovirus package, transduction and transfection. Control short hairpin (sh)RNA and specific sh-RNAs targeting GRP94 (cat. no. sc-44304) were purchased from Santa Cruz Biotechnoogy, Inc. (Dallas, TX, USA), and the corresponding sequences were cloned into the pSIREN-RetroQ plasmid (Addgene, Inc.) for retrovirus production with HCMs. For transfection, the FAM modified 2'-OMe-oligonucleotides were chemically synthesized and purified by high-performance liquid chromatography (Shanghai GenePharma, Co., Ltd., Shanghai, China). The miR-150 mimics were composed of RNA duplexes with the following sequence: 5'-UCU CCC AAC CCU UGU ACC AGU G-3'. The sequences of miR-150 inhibitor and scramble oligonucleotides were as follows: 5'-CAC UGG UAC AAG GGU UGG GAG A-3'; and 5'-CCG AAA CCU CGG UUG AUU GCG G-3'. Cells were transfected using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) at a final concentration of 100 nM. At 24 h post-transfection, the culture medium was changed. After 48 h, cells were harvested for analysis.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RNA extraction was performed using TRIzol reagent, according to the manufacturer's protocol (Invitrogen; Thermo Fisher Scientific, Inc.). Synthesis of cDNA was performed by RT reactions with 4 µg total RNA using Moloney murine leukemia virus reverse transcriptase (Invitrogen; Thermo Fisher Scientific, Inc.) with oligo dT (15) primers (Fermentas; Thermo Fisher Scientific, Inc.) as described by the manufacturer. miR-150 level was quantified by the mirVana qRT-PCR miRNA detection kit (Ambion; Thermo Fisher Scientific, Inc.) in conjunction with qPCR with SYBR Green (Bio-Rad Laboratories, Inc., Hercules, CA, USA; 95˚C for 5 min, followed by 35 cycles of 95˚C for 15 sec, 60˚C for 30 sec, and 72˚C for 30 sec). After circle reaction, the quantitation cycle (Cq) was determined and relative miR-150 level was calculated based on the Cq values and normalized to U6 level in each sample using the 2 -∆∆Cq method (20) . PCR was performed with the following primers: GRP94, forward 5'-AGC AAG ACG TGT TCG ATT C-3' and reverse 5'-CCT CAA TTT TGT CAA GGG TG-3'; GAPDH, forward 5'-GCA CCG TCA AGC TGA GAA C-3' and reverse 5'-TGG TGA AGA CGC CAG TGG A-3'.
Western blotting. HCMs were extracted in NP-40 buffer, followed by 5-10 min boiling and centrifugation (12,000 x g for 15 min at 4˚C) to obtain the supernatant. Samples containing 50 µg protein were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Inc.). After blocking with 5% (w/v) non-fat dry milk in TBS and 0.1% (w/v) Tween 20 (TBST), the membranes were incubated with an anti-GRP94 primary antibody (cat. no. sc-32249; 1:500; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h and normalized to β-actin (cat. no. sc-130065; 1:2,000; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h. After three washes with TBST, the membranes were next incubated with a horseradish peroxidase-conjugated secondary antibody (cat. no. sc516102; 1:10,000; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h and subsequently visualized with chemiluminescence (Thermo Fisher Scientific, Inc.). Signals were assessed using Quantity One ® software (version 4.5; Bio Rad Laboratories, Inc.).
Statistical analysis. Data are presented mean ± standard error for each group. All statistical analyses were performed by using PRISM version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Inter-group differences were analyzed by one-way analysis of variance followed by Tukey's post hoc test to compare the group means. P<0.05 was considered to indicate a statistically significant difference.
Results
Hypoxia induces HCM death. The effect of hypoxia-induced HCMs apoptosis was examined by the MTT assay and TUNEL assay. Compared with the control group, the cell viability was significantly decreased following exposure to hypoxia in a time-dependent manner (Fig. 1A) . TUNEL analysis was performed, and the results demonstrated that the relative percentage of living cells after hypoxia treatment for 12 or 24 h markedly decreased compared with the control group (Fig. 1B) . Furthermore, caspase-3 ( Fig. 1C) and LDH (Fig. 1D ) levels were increased in HCMs subjected to hypoxia for 12 or 24 h, which indicated that HCMs suffered hypoxia-associated injuries.
Hypoxia inhibits miR-150 expression in HCMs.
The levels of miR-150 was detected by RT-qPCR assay, and the results demonstrated that miR-150 expression levels in the hypoxia-treated group decreased by nearly 56, 48 and 40% at 12, 24 and 48 h, respectively, vs. the control group ( Fig. 2A) . To validate whether miR-150 mimics or inhibitors stable expression in HCMs, miR-150 mimics or inhibitors was transfected into HCMs by adenovirus-mediated gene transfer. RT-qPCR confirmed the elevated level of miR-150 in HCMs transfected with miR-150 mimics and the reduced level of miR-150 in HCMs transfected with miR-150 inhibitors (Fig. 2B) . As hypoxia treatment was already observed to markedly inhibit miR-150 expression in HCMs, to validate whether miR-150 regulates hypoxia-induced HCMs apoptosis, MTT assay and Annexin V/PI double-staining followed by flow cytometry analysis were performed. As presented in Fig. 2C , HCMs transfected with miR-150 mimics exhibited a significant increase in cell viability in the presence of hypoxia. However, miR-150 inhibitors markedly reinforced hypoxia-induced decrease in cell viability. Overexpression of miR-150 markedly reversed hypoxia-induced HCMs apoptosis, whereas miR-150 inhibitors significantly increased cell apoptosis in the presence of hypoxia ( Fig. 2D and E) .
GRP94 is a direct target of miR-150.
To explore the molecular mechanism of miR-150 in hypoxia-induced HCMs apoptosis, bioinformatics analysis indicated that GRP94 is a potential target of miR-150 in mammals (Fig. 3A) , which serves a critical role in ER stress-induced cardiomyocyte apoptosis and heart failure (21). To validate whether miR-150 regulates GRP94 directly through a putative binding site in HCMs, the GRP94 3'-UTR (wild-type or mutant) in the predicted miRNA binding site was cloned into the luciferase gene (pSiCHECK2). Following cotransfection with the pSiCHECK2 vectors and miR-150 mimics or the control miRNA (miR-Con), the findings demonstrated that overexpressing miR-150 in HCMs significantly decreased luciferase activity in the wild-type GRP94 3'-UTR. However, following transfection of miR-150 mimics into GRP94 mutant HCMs, the luciferase activity did not exhibit a significant difference compared with the control group (Fig. 3B) . To further assess whether miR-150 regulates GRP94 expression in HCMs, the expression of GRP94 was assessed by western blotting analysis in miR-150 mimic-or miR-150 inhibitor-transfected HCMs. The results indicated that overexpressing miR-150 markedly decreased the protein expression of GRP94 in HCMs (Fig. 3C) . In contrast, inhibition of miR-150 in HCMs resulted in upregulation of GRP94 protein expression (Fig. 3D) .
GRP94 is involved in the effect of miR-150 on hypoxia-induced
HCMs apoptosis. The mRNA (Fig. 4A) and protein (Fig. 4B) expression levels of GRP94 were significantly increased in hypoxia-injured HCMs. To further understand the apoptosis mechanisms, sh-GRP94, miR-150 mimics or miR-150 inhibitors was co-transfected into hypoxia-injured HCMs. As presented in Fig. 4C , GRP94 knockout increased the cell viability of hypoxia-impaired HCMs with miR-150 mimics or miR-150 inhibitors transfection. Furthermore, GRP94 knockout could inhibit apoptosis and caspase-3 levels in hypoxia-impaired HCMs transfected with miR-150 mimics or miR-150 inhibitors ( Fig. 4D and E) .
Discussion
The results of the present study demonstrated that hypoxia directly induces HCM apoptosis, and the expression of miR-150 was markedly decreased in hypoxia-injured HCMs. Therefore, it was hypothesized that miR-150 may serve an important role in hypoxia-induced HCM apoptosis. Notably, further study demonstrated that overexpressing miR-150 significantly reversed hypoxia-induced HCM death. In contrast, miR-150 inhibitors markedly reinforced a hypoxia-induced decrease in cell apoptosis. The molecular mechanism findings indicated that GRP94 as a direct target of miR-150 was involved in hypoxia-induced HCM apoptosis. These findings suggested that downregulation of GRP94 expression by miR-150 or GRP94 knockout protected against hypoxia-induced HCMs apoptosis. miR-150 is strictly expressed in cardiomyocytes and cardiac fibroblasts, and serves a pivotal role of cardiomyocyte survival during cardiac injury (14, 22) . Overexpressing miR-150 prevents high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300 (23) . In contrast, miR-150 aggravates H 2 O 2 -induced cardiac myocyte injury by downregulating the c-myb gene (24) . Furthermore, the expression of miR-150 in cardiac tissues is decreased in myocardial infarction and cardiac fibrosis induced by pressure overload (25) . In addition, adenoviral overexpression of miR-150 causes a reduction in cardiomyocyte size (26) . However, the potential roles of miR-150 have not been evaluated in hypoxia-induced HCM apoptosis. The present study further validated that miR-150 expression is decreased in hypoxia-injured HCMs. miR-150 deficiency reinforced hypoxia-induced HCM apoptosis. These findings suggested that downregulation of miR-150 at least partially promotes the progression of cardiovascular diseases.
A previous study verified that miR-150 expression is inhibited in hypoxia-induced hepatocytes (27) . These research outputs suggested that miR-150 may be a novel anti-hypoxic miRNA, and reveal that miR-150 negatively regulates its target gene GRP94.
GRP94 as a molecular chaperone is involved in the maintenance of cell survival and has been demonstrated to serve important roles in ER stress-induced myocardial apoptosis (28) . A previous study revealed GRP94 as the only SR calcium-binding protein that is increased during chronic atrial fibrillation (29) . However, the upstream signals that regulate GRP94 expression in HCMs remain unclear. The present study demonstrated that miR-150 is capable of targeting the 3'-UTR of GRP94 to regulate hypoxia-induced HCMs apoptosis. The results also revealed that GRP94 knockout suppressed cell apoptosis of hypoxia-impaired HCMs transfected with miR-150 mimics or miR-150 inhibitors, suggesting that a post-transcriptional regulatory mechanism exists between GRP94 and miR-150 in the context of hypoxia-induced HCM apoptosis.
In conclusion, these results suggested that the expression of miR-150 in HCMs is downregulated following hypoxia treatment. Overexpressing miR-150 inhibited hypoxia-induced HCM apoptosis by downregulating GRP94 expression. These findings might provide novel insight for the therapy of hypoxia-induced myocardial I/R injury.
